Trial Profile
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms BEAT-meso
- 29 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2021 Planned number of patients changed from 320 to 400.
- 30 Apr 2021 Planned End Date changed from 31 Dec 2024 to 31 Jan 2024.